medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2014; 13 (4)


Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin

TMM de Kanter C, van Luin M, Solas C, Burger DM, Vrolijk JM

Idioma: Ingles.
Referencias bibliográficas: 12
Paginas: 452-455
Archivo PDF: 62.52 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

  2. Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2012; doi: 10.1016/j.jhep.2012.10.027. [Epub ahead of print]

  3. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 1620-8.

  4. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674-80.

  5. FDA. Incivek: Prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm. (accessed 2013).

  6. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; 55: 4569-74.

  7. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33: 171-87.

  8. Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol 2010; 22: 644-50.

  9. Aarnoutse RE, Burger DM. When should we fear for statin interactions. In: Vissers, Kastelein, Stroes (eds.). Evidence- Based Management of Lipid Disorders. Chap. 17. Castle Hill Barns, UK: TFM Publishing limited; 2010.

  10. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009; 11: 272-8.

  11. http://www.hep-druginteractions.org/

  12. http://www.drugs.com/drug-interactions/telaprevir.html




2020     |     www.medigraphic.com